Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 355

1.

Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected].

Heidelbaugh JJ, Goldberg KL, Inadomi JM.

Am J Gastroenterol. 2009 Mar;104 Suppl 2:S27-32. doi: 10.1038/ajg.2009.49. Review. Erratum in: Am J Gastroenterol. 2009 Apr;104(4):1072. Am J Gastroenterol. 2009 Mar;104(2 Suppl):S39.

PMID:
19262544
2.

A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.

Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G.

Am J Gastroenterol. 2000 Feb;95(2):395-407.

PMID:
10685741
3.

[Gastroesophageal reflux disease: pathogenetic basis of differentiated tactics of treatment].

Tkachenko EI, Uspenskiĭ IuP, Karateev AE, Bakulin IG, Pakhomova IG.

Eksp Klin Gastroenterol. 2009;(2):104-14. Russian.

PMID:
19552028
4.

Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.

Kothari S, Nelson SP, Wu EQ, Beaulieu N, McHale JM, Dabbous OH.

Curr Med Res Opin. 2009 Nov;25(11):2703-9. doi: 10.1185/03007990903307755.

PMID:
19775195
5.

Management strategies for gastroesophageal reflux disease.

Bak YT.

J Gastroenterol Hepatol. 2004 Sep;19 Suppl 3:S49-53. Review.

PMID:
15324382
6.

Economic reflections on proton pump inhibitor therapy for non-erosive reflux disease.

Moayyedi P.

Digestion. 2008;78 Suppl 1:61-9. doi: 10.1159/000151257. Epub 2008 Oct 2. Review.

PMID:
18832842
7.

Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: clinical and economic consequences.

Barletta JF, Sclar DA.

Pharmacoeconomics. 2014 Jan;32(1):5-13. doi: 10.1007/s40273-013-0119-5. Review.

PMID:
24271943
8.

A practice-based approach for converting from proton pump inhibitors to less costly therapy.

Lucas LM, Gerrity MS, Anderson T.

Eff Clin Pract. 2001 Nov-Dec;4(6):263-70.

PMID:
11769299
9.

Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.

Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, Passariello A, Manguso F, Morelli L, Guarino A; Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP).

Pediatrics. 2006 May;117(5):e817-20.

PMID:
16651285
10.

Treatment patterns and symptom control in patients with GERD: US community-based survey.

Chey WD, Mody RR, Wu EQ, Chen L, Kothari S, Persson B, Beaulieu N, Lu M.

Curr Med Res Opin. 2009 Aug;25(8):1869-78. doi: 10.1185/03007990903035745.

PMID:
19530980
11.

The pharmacological management of gastroesophageal reflux disease.

Lowe RC, Wolfe MM.

Minerva Gastroenterol Dietol. 2004 Sep;50(3):227-37. Review.

13.

Cost-Effectiveness of Histamine2 Receptor Antagonists Versus Proton Pump Inhibitors for Stress Ulcer Prophylaxis in Critically Ill Patients.

Hammond DA, Kathe N, Shah A, Martin BC.

Pharmacotherapy. 2017 Jan;37(1):43-53. doi: 10.1002/phar.1859. Epub 2016 Dec 20.

PMID:
27809338
14.

Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs?

Bruley des Varannes S, Coron E, Galmiche JP.

Best Pract Res Clin Gastroenterol. 2010 Dec;24(6):905-21. doi: 10.1016/j.bpg.2010.09.004. Review.

PMID:
21126703
15.

Economic considerations in the treatment of gastroesophageal reflux disease: a review.

O'Connor JB, Provenzale D, Brazer S.

Am J Gastroenterol. 2000 Dec;95(12):3356-64. Review.

PMID:
11151862
16.

Overutilization of proton-pump inhibitors: what the clinician needs to know.

Heidelbaugh JJ, Kim AH, Chang R, Walker PC.

Therap Adv Gastroenterol. 2012 Jul;5(4):219-32. doi: 10.1177/1756283X12437358.

17.

Marked increase in proton pump inhibitors use in Australia.

Hollingworth S, Duncan EL, Martin JH.

Pharmacoepidemiol Drug Saf. 2010 Oct;19(10):1019-24. doi: 10.1002/pds.1969.

PMID:
20623646
18.

Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.

Björnsson E, Abrahamsson H, Simrén M, Mattsson N, Jensen C, Agerforz P, Kilander A.

Aliment Pharmacol Ther. 2006 Sep 15;24(6):945-54.

19.

Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists.

Barkun AN, Adam V, Martel M, Bardou M.

Value Health. 2013 Jan-Feb;16(1):14-22. doi: 10.1016/j.jval.2012.08.2213.

20.

Stress ulcer prophylaxis in hospitalized patients not in intensive care units.

Grube RR, May DB.

Am J Health Syst Pharm. 2007 Jul 1;64(13):1396-400. Review.

PMID:
17592004

Supplemental Content

Support Center